2024

1. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

   Cancers, Vol. 16, Núm. 9

2. An algorithm for the diagnosis of betalactam allergy, 2024 update

   Allergy: European Journal of Allergy and Clinical Immunology

3. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

   Haematologica

4. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

   Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

5. Cajal’s contributions to vestibular research

   Frontiers in Neuroanatomy , Vol. 18

6. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

   British Journal of Surgery, Vol. 111, Núm. 3

7. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

   Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

8. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

   The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

9. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

   Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

10. Factors associated with discharge home in older patients admitted to emergency department observation units: Looking for a predictive scale

    Journal of Evaluation in Clinical Practice

11. Hyperactive delirium during emergency department stay: analysis of risk factors and association with short-term outcomes

    Internal and Emergency Medicine, Vol. 19, Núm. 2, pp. 535-545

12. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 17, pp. 3704-3714

13. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

14. Impact of primary aldosteronism on kidney function: Results from the SPAIN-ALDO registry

    Journal of Hypertension, Vol. 42, Núm. 10, pp. 1805-1812

15. Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch

    Transplantation, Vol. 108, Núm. 3, pp. 787-801

16. Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial

    The Lancet Respiratory Medicine, Vol. 12, Núm. 3, pp. 195-206

17. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

18. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

    Leukemia

19. Perioperative management of blood pressure in neurocritical patients: Consensus reached through the Delphi method

    Perioperative Care and Operating Room Management, Vol. 35

20. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603